Pertuzumab
Based on 10 publication(s) in Google Scholar
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
For research use only. We do not sell to patients.
- Purity: 99.8%
- CAS No.: 380610-27-5
- Molecular Weight:145.44 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pertuzumab
More- Nat Nanotechnol. 2025 Feb;20(2):296-302. [Abstract]
- Anal Chim Acta. 2021 Apr 15:1154:338306. [Abstract]
- J Invest Dermatol. 2023 May;143(5):832-841.e4. [Abstract]
- Commun Biol. 2024 May 28;7(1):652. [Abstract]
- Int J Cancer. 2024 Jul 15;155(2):324-338. [Abstract]
- Sci Rep. 2024 Feb 14;14(1):3771. [Abstract]
- EJNMMI Radiopharm Chem. 2025 Apr 4;10(1):16. [Abstract]
- Breast Cancer Res Treat. 2026 Mar 13;216(3):25. [Abstract]
- bioRxiv. 2026 Jun 19.
- SSRN. 2025 Jul 25.
Customer Validation & Images
-
In Vivo Imaging
All EGFR Isoforms
More
Biological Activity
Human IgG1 kappa
Human
|
HER2 |
Trastuzumab and Pertuzumab are highly synergistic inhibitors of BT474 breast cancer cell survival. The combination of trastuzumab and Pertuzumab mediates a loss of up to 60% of cells at doses in which individual drugs do not alter cell survival. The combination of trastuzumab and Pertuzumab reduces the percentage of proliferating (S-phase) cells by more than 2-fold. A combination of trastuzumab and Pertuzumab inhibits cell proliferation and survival to a greater degree than does either agent alone[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized HER2/CD340 Protein, Human can bind Pertuzumab. The EC50 for this effect is 42.59 ng/mL. -
Pertuzumab has a significant ADCC effect on SK-BR-3 cells in a dose-dependent manner.The EC50 for this effect is 61.54 and 74.56 ng/mL.
Chemical Information
-
CAS No. 380610-27-5
-
Appearance Liquid
-
Molecular Weight 145.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Pertuzumab]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Nat Nanotechnol
2025 Feb;20(2):296-302. PMID: 39468359 -
Anal Chim Acta
Calibration for quantitative Fc-glycosylation analysis of therapeutic IgG1-type monoclonal antibodies by using glycopeptide standards. [Abstract]2021 Apr 15:1154:338306. PMID: 33736796 -
J Invest Dermatol
Cathelicidin Antimicrobial Peptide LL37 Induces TLR8 and Amplifies IL-36γ and IL-17C in Human Keratinocytes. [Abstract]2023 May;143(5):832-841.e4. PMID: 36496195 -
Commun Biol
Epitope binning for multiple antibodies simultaneously using mammalian cell display and DNA sequencing. [Abstract]2024 May 28;7(1):652. PMID: 38806676 -
Int J Cancer
Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]2024 Jul 15;155(2):324-338. PMID: 38533706 -
Sci Rep
Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC. [Abstract]2024 Feb 14;14(1):3771. PMID: 38355949
Pertuzumab purchased from MedChemExpress. Usage Cited in: Sci Rep. 2024 Feb 14;14(1):3771. [Abstract]
In vivo probing of HER2 and EGFR in FADU tumors with immune-PET imaging. FADU tumors were injected and imaged with [89Zr]-pertuzumab PET imaging. Pertuzumab (10 mg/mL) was conjugated with 0.4 mg deferoxamine (DFO). DFO–pertuzumab was labeled with [⁸⁹Zr] at 6 µCi/µg, and approximately 66.8 ± 15 µCi [⁸⁹Zr]‑pertuzumab (n = 6) was injected intravenously. Approximately 10–12 µg of radiolabeled antibody was administered before imaging.
-
EJNMMI Radiopharm Chem
2025 Apr 4;10(1):16. PMID: 40183827 -
Breast Cancer Res Treat
Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer. [Abstract]2026 Mar 13;216(3):25. PMID: 41824101 -
-
Protocol
BT474 cells are seeded at 5×104 cells/well in 12-well dishes. After 24 h, cells are treated in triplicate with 2-fold serial dilutions of trastuzumab, Pertuzumab, or both drugs simultaneously at a fixed 1:1 ratio at low doses ranging from 0.9 ng/mL to 10 ng/mL. After 5 days, cells are trypsinized and counted by trypan blue exclusion. Growth inhibition is calculated as the percentage of viable cells compared with untreated cultures[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice: Calu-3 or KPL-4 tumors (100 mm3) are treated with trastuzumab (30 mg/kg loading dose, then 15 mg/kg weekly), Pertuzumab (30 mg/kg loading dose, then 15 mg/kg weekly), or both, administered i.p. for the duration of the study. Tumor volumes and body weights are measured twice weekly. For the acute study, advanced Calu-3 tumors of 400 mm3 are treated once with trastuzumab and/or Pertuzumab at a dose of 30 mg/kg. Samples are harvested 7 d later for immunohistochemistry (IHC) and Western blot analysis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Nahta R, et al. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survivalof breast cancer cells. Cancer Res. 2004 Apr 1;64(7):2343-6. [Content Brief]
[2]. Scheuer W, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009 Dec 15;69(24):9330-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz